Poly(ADP-Ribose) Links the DNA Damage Response and Biomineralization
Cell Reports, 2019 Summary: Biomineralization of the extracellular matrix is an essential, regulated process. Inappropriate mineralization of bone and the vasculature has devastating effects on patient health, yet an integrated understanding of the chemical and cell ...
Karin H. Müller +26 more
doaj +1 more source
The suppression of DNA repair induced by PARP-1 inhibitors rucaparib and olaparib in combination with the radiopharmaceutical 131I-MIBG in noradrenaline transporter-expressing xenograft tumors [PDF]
, 2018 No abstract ...
Gaze, Mark N. +4 more
core +1 more source
Poly (ADP-Ribose) Polymerase Inhibitors in Patients With Urothelial Cancer
Clinical Genitourinary Cancer, 2023 Poly ADP-ribose polymerase inhibitors (PARPis) have clinical activity in several cancers. The rationale of their therapeutic use in urothelial cancer (UC) resides in the high homologous-recombination repair (HRR) deficiency (HRD) prevalence and potential cross-sensitivity with platinum-based chemotherapy (PBCT).
Gamba, Teresa +5 more
openaire +2 more sources
Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment [PDF]
, 2016 Background: Despite standard treatment for epithelial ovarian cancer (EOC), that involves cytoreductive surgery followed by platinum-based chemotherapy, and initial high response rates to these, up to 80 % of patients experience relapses with a median ...
Caruso, Davide +4 more
core +2 more sources
Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response
Genome Medicine, 2018 Editorial summary Inhibitors of poly(ADP-ribose) polymerase (PARPi) have entered the clinic for the treatment of patients with cancers that lack homology-directed DNA repair, but drug resistance remains a clinical hurdle.
Paola Francica, Sven Rottenberg
doaj +1 more source
Poly(ADP-ribose) polymerase inhibitors as cancer therapy
Frontiers in Bioscience, 2013 Poly(ADP-ribose) polymerase (PARP) inhibitors are pharmacologic agents which primarily inhibit the PARP-1 and PARP-2 enzymes within the cell. Inhibition of PARP results in failure of base-excision repair (BER) to correct single-stranded breaks in DNA.
John F, Hilton +3 more
openaire +2 more sources
Radiotherapy-Poly(ADP-ribose) Polymerase Inhibitor Combinations: Progress to Date [PDF]
Seminars in Radiation Oncology, 2022 Radiation resistance remains a huge clinical problem for cancer patients and oncologists in the 21st century. In recent years, the mammalian DNA damage response (DDR) has been extensively characterized and shown to play a key role in determining cellular survival following ionizing radiation exposure.
Derby, Sarah J. +2 more
openaire +2 more sources
Targeting DNA damage response deficiency in the treatment of breast cancer [PDF]
Zhongguo aizheng zazhi, 2022 DNA damage response (DDR) deficiency has been one of the emerging targets in treating breast cancer in recent years. The DDR pathway is essential for the identification, signal transduction and repair of DNA damage.
JIN Yizi, LIN Mingxi, ZHANG Jian
doaj +3 more sources
PARP inhibition: a promising therapeutic target in ovarian cancer [PDF]
, 2015 Ovarian cancer is burdened by the highest mortality rate among gynecological cancers. Gold standard is represented by the association of platinum-taxane -based chemotherapy and radical surgery.
Abdul Halim, T +14 more
core +1 more source
The clinical development of inhibitors of poly(ADP-ribose) polymerase
Annals of Oncology, 2011 A number of inhibitors of DNA repair have been evaluated or are undergoing development as potential cancer treatments. Inhibitors of poly(ADP-ribose) polymerase (PARP) are of particular interest in treating hereditary breast cancers occurring in patients who are carriers of BRCA1 or BRCA2 mutations. In vitro PARP inhibitors are highly cytotoxic to cell
H, Calvert, A, Azzariti
openaire +2 more sources